antibodies

People with multiple sclerosis (MS) tend to have high levels of antibodies targeting the Epstein-Barr virus (EBV), but levels of these antibodies are not associated with disease activity or clinical worsening among MS patients. That’s according to the study, “Evaluating the role of anti-EBV antibodies…

Antibodies against a protein found in neurons and in nerve supporting cells, may play a role in driving multiple sclerosis (MS), a study indicates. Researchers examined immune responses against more than 23,000 human proteins, and the MLC1 protein emerged as one of the top hit proteins targeted by immune…

Researchers have identified a distinct profile of self-reactive antibodies that appear in the blood years before the first clinical signs of multiple sclerosis (MS), which they believe could be used to help diagnose the neurodegenerative disease. The antibodies were found in about 10% of people who developed MS and…

An antibody biomarker may help to distinguish people with a disease that resembles multiple sclerosis (MS), but may actually be its own clinical disorder, according to a new study. The biomarker was present in about 1% of MS patients and in 6% of those with a related demyelinating condition…

It’s been almost two and a half years since my first COVID-19 vaccine — eight months since my most recent booster — and my COVID-19 antibodies seem to still be doing their thing. I know this because, after having nine test tubes of blood drawn, the lab results…

Clusters of immunoglobulin G (IgG) antibodies in the blood of multiple sclerosis (MS) patients appear to contribute to the nerve cell death that marks the neurodegenerative disease, according to a recent study. IgG antibodies harvested from the blood of MS patients drove nerve cell death in cell cultures, whereas antibodies…

Scientists have developed new skin patches that could offer a more convenient and less painful way to administer antibody-based medicines to people with multiple sclerosis (MS) and other disorders. “The developed [skin] patch is minimally invasive, self-administrable, and designed to be fully embedded into the skin with a short…

Primary progressive multiple sclerosis (PPMS) is driven by antibodies in the cerebrospinal fluid (CSF), the liquid around the brain and spinal cord — but this is not the case in the more common relapsing forms of MS — a new study done in mice suggests. Researchers say this result…

Scientists have identified a number of antibodies that can bind to the Epstein-Barr virus (EBV) — a major risk factor for multiple sclerosis (MS) — and prevent its infection of human cells. The antibodies might offer new approaches to treat or prevent infection in groups of people most…

An infection with the Epstein-Barr virus (EBV) consistently preceded elevations in neurofilament light chain (NfL), an early biomarker of nerve cell damage, in people who went on to develop multiple sclerosis (MS), new data show. An increase in NfL levels, which is thought to occur before the clinical…

People with multiple sclerosis (MS) are significantly more likely to have antibodies against the Epstein-Barr virus (EBV) — the strongest risk factor for the disease — than healthy individuals, as well as higher levels of these antibodies, according to a Spanish study. All MS patients were positive for anti-EBV…

Among multiple sclerosis (MS) patients on rituximab, higher B-cell counts are predictive of a better antibody-based response to a vaccine for COVID-19, according to a new Swedish study. “In our study, the B-cell level in patients given Rituximab was the only factor that influenced the ability to form antibodies…

A team of researchers has discovered that the key to bypassing the blood-brain barrier — a semipermeable border that protects the brain against toxins in the blood but also blocks potential treatments — is the Unc5B receptor in the endothelial cells that line the tiny blood vessels in the brain.

While people with multiple sclerosis (MS) taking anti-CD20 therapies do not mount a robust antibody response after getting vaccinated against COVID-19, the vaccines do strongly activate other parts of the immune system that are likely to be helpful in fighting the virus, a new study shows. “The message…

Long-term use of Kesimpta (ofatumumab) among people with multiple sclerosis (MS) did not substantially lower their antibody levels, allowing them to retain an ability to fight infections, new data from a Phase 3 clinical trial indicate. “These long-term results continue to support Kesimpta as a high-efficacy, first-choice treatment with…

Targeting the MOSPD2 protein may prevent immune cells known as monocytes from entering the central nervous system (CNS), which may significantly ease brain inflammation and myelin damage in multiple sclerosis (MS), a study in mice suggests. VBL Therapeutics, the company leading the study, has developed…

Supporting evidence that infection with Epstein-Barr virus (EBV) could be one of the root causes of multiple sclerosis (MS), a recent study found all of its 901 early disease patients carry antibodies against this virus, meaning that all are or have been exposed to it. The study, “…

A new tiny sensor is able to detect antibodies against myelin, the protective coating of nerve cell axons whose destruction is a hallmark of multiple sclerosis (MS), potentially allowing for a diagnosis in early disease stages, researchers report. It also offers the possibility of distinguishing multiple sclerosis from neuromyelitis optica, a…

A variant of the HLA-DRB1 gene — called HLA-DRB1*03 — appears to predispose people to developing multiple sclerosis (MS) in childhood, and to correlate with greater disease activity among those who do, a study in Greek patients suggests. The research also points to a protective role of one other variant of this…

Human herpesvirus 6A (HHV-6A), but not a widespread variant of the virus called HHV-6B, could be one of the root causes of multiple sclerosis (MS), new research suggests. Compared to healthy people, those with MS show greater numbers of antibodies to HHV-6A viruses, reflecting greater exposure to…

Infection with the human herpesvirus (HHV)-6A may increase the likelihood of having multiple sclerosis (MS), according to a new national study in Sweden. The research, “Serological response against HHV-6A is associated with increased risk for multiple sclerosis,” was presented by Anna Fogdell-Hahn, PhD, associate professor at the…

Treatment for more than six years with Ocrevus (ocrelizumab) is linked to lower levels of blood antibodies among people with primary progressive multiple sclerosis (PPMS) and relapsing MS, but rates of serious infections also remain low, an analysis of data from three Phase 3 trials show. Dropping below a certain…

Iranian researchers have identified another herpes virus that may increase the risk of a person developing multiple sclerosis. The team identified the human herpesvirus 6, or HHV6, as a potential risk factor for MS through a meta-analysis of several studies. They published their findings, “Relationship of Human…

The Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis in the early stages of a disorder. The test, the first of its kind in the United States, looks for an antibody against a protein known as myelin oligodendrocyte glycoprotein…

Magnetic resonance imaging (MRI) brain scans of children could reveal changes associated with multiple sclerosis (MS) before any symptoms are developed, according to a study by scientists at Yale University School of Medicine. The findings suggest that brain and spinal cord scans can identify children at high risk for developing MS.

Secondary progressive multiple sclerosis (SPMS) patients have larger quantities of certain antibodies to the stomach ulcer bacterium Helicobacter pylori than those with relapsing-remitting multiple sclerosis (RMSS), finds a Greek study which also showed that MS patients in general differ from healthy people in this aspect. Although researchers at the University of Thessaly think…